Business
EnVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H25
EnVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in
About this update from Envveno Medical Corporation
[{"type":"text","content":"IRVINE - enVVeno Medical Corporation (NASDAQ: NVNO) ('enVVeno' or the 'Company'), a company setting new standards of care for the treatment of deep venous disease, today reported financial results for the first quarter 2025.Robert Berman, enVVeno Medical's Chief Executive Officer, commented 'In the first quarter, we continued to present our compelling 1-year data from the U.S. pivotal trial at leading global, scientific conferences to socialize and engage directly with leading vascular surgeons as we lay the foundation for the potential phased market entry of the VenoValve, pending FDA approval. We have also maintained a strong financial position an important advantage in the current market conditions. We remain confident that 2025 will be a pivotal year as we prepare for our transition from a development-stage company to a commercial enterprise.'\nSummary of Financial Results for the First Quarter 2025\nThe Company ended the quarter with $38.9 million in cash and investments. Based on management's current expectations, this capital has the potential to fund the Company through the anticipated FDA decision for VenoValve, the initiation of commercialization preparations for VenoValve and the commencement of the enVVe pivotal study.\nCash burn for the quarter was $4.0 million, consistent with the Company's projected cash burn rate of approximately $4-5 million per quarter. The Company anticipates that its cash burn rate will increase from current levels once commercialization of the VenoValve begins.\nThe Company reported net losses of $4.5 million and $5.0 million for the three months ended March 31, 2025 and 2024, respectively, representing a decrease in net loss of $0.5 million, primarily resulting from a decrease in operating expenses.\nClinical Program Highlights\nVenoValve: Surgical Replacement Venous Valve\nVenoValve PMA application seeking U.S. Food and Drug Administration (FDA) approval submitted; Decision expected in H2 2025.\nThe Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the SAVVE procedure, including approximately 1.5 million with active venous ulcers.\nenVVe: Non-Surgical Transcatheter Based Replacement Venous Valve\nSuccessfully completed final wave for the shorter-term subjects in 6-month pre-clinical GLP study. The follow-up ...